Medvolt vs Valo Health (2026)

Medvolt and Valo Health sit at opposite ends of how early small molecule discovery is bought, though both apply AI to it for drug companies. Medvolt, from Pune, sells MedGraph as modules and as projects its scientists deliver, and pitches it as affordable for organizations of different sizes. Rubie handles drug repurposing and target identification, Topaaz generates new chemical entities, EDGE builds knowledge graphs from the literature and Oopal runs free energy perturbation, and the same platform designs peptides, antibodies, oligonucleotides and enzymes. It also runs five preclinical programs of its own, most in oncology, with experimental work alongside ACTREC-TMC, and it says its platform cuts preclinical discovery time threefold and costs fifteenfold, without a published basis. Valo Health does not sell tools. It enters collaborations that bring its own data, more than 17 million de identified patient records, together with its causal biology and closed loop chemistry to a partner's disease area, and it is paid in upfront, milestone and royalty payments; Novo Nordisk's expanded deal carries up to $190 million near term. A smaller biotech or research group that wants in silico modules or a scoped project on a tight budget fits Medvolt. A large drug company ready to commit to a multi program discovery partnership built on human data fits Valo.